Squarepoint Ops LLC Has $1.42 Million Holdings in Clovis Oncology (CLVS)

Squarepoint Ops LLC boosted its stake in shares of Clovis Oncology (NASDAQ:CLVS) by 1,049.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 78,985 shares of the biopharmaceutical company’s stock after acquiring an additional 72,116 shares during the quarter. Squarepoint Ops LLC owned about 0.15% of Clovis Oncology worth $1,419,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Samlyn Capital LLC purchased a new stake in shares of Clovis Oncology in the fourth quarter valued at approximately $18,054,000. Orbimed Advisors LLC lifted its holdings in Clovis Oncology by 23.2% during the fourth quarter. Orbimed Advisors LLC now owns 2,752,200 shares of the biopharmaceutical company’s stock worth $49,430,000 after buying an additional 517,630 shares during the period. Elk Creek Partners LLC purchased a new stake in Clovis Oncology during the fourth quarter worth $6,828,000. Dimensional Fund Advisors LP purchased a new stake in Clovis Oncology during the fourth quarter worth $5,641,000. Finally, Macquarie Group Ltd. lifted its holdings in Clovis Oncology by 27.1% during the third quarter. Macquarie Group Ltd. now owns 878,530 shares of the biopharmaceutical company’s stock worth $25,802,000 after buying an additional 187,071 shares during the period.

Shares of CLVS stock opened at $24.25 on Tuesday. The firm has a market cap of $1.31 billion, a PE ratio of -3.43 and a beta of 2.08. The company has a debt-to-equity ratio of 3.93, a quick ratio of 4.34 and a current ratio of 4.55. Clovis Oncology has a 12-month low of $11.50 and a 12-month high of $65.24.

Clovis Oncology (NASDAQ:CLVS) last released its earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by ($0.16). Clovis Oncology had a negative net margin of 385.80% and a negative return on equity of 147.39%. The firm had revenue of $30.40 million during the quarter, compared to analyst estimates of $30.46 million. During the same period in the previous year, the company earned ($1.04) earnings per share. Clovis Oncology’s revenue was up 78.4% on a year-over-year basis. On average, analysts predict that Clovis Oncology will post -7.06 earnings per share for the current year.

In other Clovis Oncology news, insider Lindsey Rolfe sold 1,731 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $29.29, for a total transaction of $50,700.99. Following the sale, the insider now directly owns 16,497 shares of the company’s stock, valued at approximately $483,197.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James C. Blair sold 17,056 shares of the stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $27.79, for a total transaction of $473,986.24. Following the sale, the director now directly owns 13,439 shares in the company, valued at $373,469.81. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,782 shares of company stock worth $576,755. 10.20% of the stock is owned by insiders.

A number of analysts have weighed in on the company. ValuEngine upgraded Clovis Oncology from a “sell” rating to a “hold” rating in a report on Monday. Zacks Investment Research raised Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Friday. BidaskClub downgraded Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, March 20th. SunTrust Banks upped their price target on Clovis Oncology to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, February 27th. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $27.00 price target on shares of Clovis Oncology in a research report on Wednesday, February 27th. One analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $45.85.

ILLEGAL ACTIVITY WARNING: “Squarepoint Ops LLC Has $1.42 Million Holdings in Clovis Oncology (CLVS)” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2019/04/02/squarepoint-ops-llc-has-1-42-million-holdings-in-clovis-oncology-clvs.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Further Reading: Stop Order

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.